Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 270
- Registration Number
- NCT04736589
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-06-04
- Target Recruit Count
- 60
- Registration Number
- NCT04717531
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment
- Conditions
- Lung Cancer, Non-small Cell
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 26
- Registration Number
- NCT04706949
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-24
- Target Recruit Count
- 80
- Registration Number
- NCT04683445
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2020-12-23
- Target Recruit Count
- 71
- Registration Number
- NCT04681911
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pyrotinib
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04680091
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
- Conditions
- Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04639271
- Locations
- 🇨🇳
Zhiyong Yu, Jinan, Shandong, China
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast CancerPyrotinibBreast DiseasesVinorelbineHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 208
- Registration Number
- NCT04605575
- Locations
- 🇨🇳
Zhang Jingmin, Guangzhou, China
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04486911
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04479891
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.